2010
Family outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisClinicians
2009
Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial
Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial. Schizophrenia Research 2009, 116: 118-125. PMID: 19864114, DOI: 10.1016/j.schres.2009.09.026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAttitude to HealthCaregiversCost-Benefit AnalysisDouble-Blind MethodFamilyFemaleHumansLongitudinal StudiesMaleMiddle AgedPsychiatric Status Rating ScalesQuality of LifeRegression AnalysisSchizophreniaSchizophrenic PsychologySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsSecond-generation antipsychoticsSecond-generation drugsFamily burdenTreatment assignmentInitial treatment assignmentSecond-generation medicationsClinical Antipsychotic TrialsEvidence of superiorityMedication changesCATIE trialInitial medicationPatient's symptomsAntipsychotic medicationAntipsychotic TrialsDaily livingFamily caregiversService useSide effectsMedicationsSecondary analysisPatientsIntervention effectivenessBurden factorsTrialsAntipsychotics